US5036003A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antibodies to VPF
Assignee: Genentech Inc
•
Filing: 1988-09-02
•
Granted: 1991-07-30
•
Expires: 2008-09-02
Abstract
Abstract A method of producing antibodies against vascular permeability factor (VPF) is disclosed which comprises immunizing a host animal with a peptide having an amino acid sequence as follows: <IMAGE> <IMAGE> <IMAGE> or a fragment of said peptide containing an antigenic determinant of VPF.
Inventors
- 👤 Jitka V. Olander
- 👤 Daniel T. Connolly
- 👤 Steven P. Adams
- 👤 Joseph Feder
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 02:01
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
34 words
A method of producing antibodies which block the permeability-enhancing and growth-promoting activities of vascular permeability factor (VPF) comprising immunizing an animal host with a synthetic peptide having an amino acid sequence as follows: ##STR6##
Claim 2
Independent Claim
34 words
A method of producing antibodies which block the permeability-enhancing and growth-promoting activities of vascular permeability factor (VPF) comprising immunizing an animal host with a synthetic peptide having an amino acid sequence as follows: ##STR6##
Claim 3
Independent Claim
34 words
A method of producing antibodies which block the permeability-enhancing and growth-promoting activities of vascular permeability factor (VPF) comprising immunizing an animal host with a synthetic peptide having an amino acid sequence as follows: ##STR7##
Claim 4
Independent Claim
34 words
A method of producing antibodies which block the permeability-enhancing and growth-promoting activities of vascular permeability factor (VPF) comprising immunizing an animal host with a synthetic peptide having an amino acid sequence as follows: ##STR7##
Claim 5
Independent Claim
78 words
A method of producing a monoclonal antibody which blocks the permeability-enhancing and growth-promoting activities of vascular permeability factor (VPF) comprising: (a) immunizing a mouse with a synthetic peptide having the amino acid sequence as follows: ##STR8## and in which the immunizing peptide is coupled to bovine serum albumin or thyroglobulin carrier protein, (b) harvesting spleen cells from said mouse, and (c) fusing spleen cells with mouse myeloma cells to obtain a monoclonal antibody capable of blocking VPF activity.
Claim 6
Independent Claim
78 words
A method of producing a monoclonal antibody which blocks the permeability-enhancing and growth-promoting activities of vascular permeability factor (VPF) comprising: (a) immunizing a mouse with a synthetic peptide having the amino acid sequence as follows: ##STR8## and in which the immunizing peptide is coupled to bovine serum albumin or thyroglobulin carrier protein, (b) harvesting spleen cells from said mouse, and (c) fusing spleen cells with mouse myeloma cells to obtain a monoclonal antibody capable of blocking VPF activity.
Claim 7
Independent Claim
78 words
A method of producing a monoclonal antibody which blocks the permeability-enhancing and growth-promoting activities of vascular permeability factor (VPF) comprising: (a) immunizing a mouse with a synthetic peptide having the amino acid sequence as follows: ##STR9## and in which the immunizing peptide is coupled to bovine serum albumin or thyroglobulin carrier protein, (b) harvesting spleen cells from said mouse, and (c) fusing spleen cells with mouse myeloma cells to obtain a monoclonal antibody capable of blocking VPF activity.
Claim 8
Independent Claim
78 words
A method of producing a monoclonal antibody which blocks the permeability-enhancing and growth-promoting activities of vascular permeability factor (VPF) comprising: (a) immunizing a mouse with a synthetic peptide having the amino acid sequence as follows: ##STR9## and in which the immunizing peptide is coupled to bovine serum albumin or thyroglobulin carrier protein, (b) harvesting spleen cells from said mouse, and (c) fusing spleen cells with mouse myeloma cells to obtain a monoclonal antibody capable of blocking VPF activity.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-07-29 | 1995-01-28 | 1995-07-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-07-29 | 1999-01-28 | 1999-07-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-07-29 | 2003-01-28 | 2003-07-30 | $7700.00 | Window Closed / Lapsed |